HAIP Chemo Offers OS Advantage in Advanced Intrahepatic Cholangiocarcinoma
SAN FRANCISCO — Hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine significantly improved overall survival (OS) in patients with advanced intrahepatic cholangiocarcinoma (iCCA), according to results from a phase II study. Patients treated with HAIP chemotherapy combined with systemic chemotherapy achieved a 1-year OS of 80% compared with 47% in the historical cohort treated with […]
Efgartigimod Offers Hope in Chronic Inflammatory Demyelinating Polyneuropathy
PHOENIX — A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with diagnosed chronic inflammatory demyelinating polyneuropathy (CIDP) treated with efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) saw a 61% reduction in the risk of relapse versus placebo, […]
Subcutaneous Ocrelizumab Not Inferior to IV Infusion
MILAN — An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed. During the first 12 weeks of treatment, blood levels of ocrelizumab — measured as the area under the serum concentration time curve (AUC) […]
Hormone Infusion Shows Promise for Low Sexual Desire
An infusion of the hormone kisspeptin helped improve low sexual desire in both men and women, two small trials found. In the 37-participant study of heterosexual men with hypoactive sexual desire disorder (HSDD), IV kisspeptin-54 significantly increased activity in key sexual-processing structures of the brain in response to viewing sexual videos compared with placebo (mean […]